The total return over the past 12 months is -79.67% vs. +16.94% for the S&P 500. So far it's up -68.94% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | (79.67%) | (50.22%) | (52.26%) | (28.72%) | (18.41%) | (23.42%) |
| Total Return CAGR | (79.67%) | (50.22%) | (52.26%) | (28.72%) | (18.41%) | (23.42%) |
| Revenue CAGR | +3.07% | +2.34% | (3.17%) | +19.99% | N/A | +48.55% |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Cytosorbents Corporation (CTSO)
| Year | Start price | End price | CTSO Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $12.78 | $3.97 | (68.94%) | +14.51% | (83.45%) |
| 2025 | $18.20 | $12.78 | (29.78%) | +17.72% | (47.50%) |
| 2024 | $22.20 | $18.20 | (18.02%) | +24.89% | (42.91%) |
| 2023 | $31.00 | $22.20 | (28.39%) | +26.19% | (54.58%) |
| 2022 | $83.80 | $31.00 | (63.01%) | (18.17%) | (44.84%) |
| 2021 | $159.40 | $83.80 | (47.43%) | +28.74% | (76.17%) |
| 2020 | $77.00 | $159.40 | +107.01% | +18.37% | +88.64% |
| 2019 | $161.60 | $77.00 | (52.35%) | +31.22% | (83.57%) |
| 2018 | $130.00 | $161.60 | +24.31% | (4.56%) | +28.87% |
| 2017 | $109.00 | $130.00 | +19.27% | +21.70% | (2.43%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
